Navigation Links
Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
Date:3/26/2008

MORRISTOWN, N.J., March 26 /PRNewswire/ -- Vicus Therapeutics, LLC, an oncology-focused, clinical-stage, biopharmaceutical company, announced that Navaneetha K. Rao, Vice President Clinical Research and Development, is scheduled to present at Cambridge Healthtech Institute's 15th International Molecular Medicine Tri-Conference on March 28st at 1:35 p.m. PST at the Mascone North Convention Center in San Francisco. Dr. Rao will focus on considerations that are particularly relevant to successfully executing a Phase 2 multi-center study in India including:

-- Identification and management of clinical research organizations

-- Subject recruitment

-- Principal investigators and site management

-- Project management and communication

-- Quality management

About Vicus Therapeutics

Vicus Therapeutics is a privately-held, biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of cancer supportive care indications with an initial focus on cachexia. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of oral mucositis and cancer fatigue.

For additional information, go to the Company's website: http://www.vicustherapeutics.com.


'/>"/>
SOURCE Vicus Therapeutics, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Vicus Therapeutics Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels
3. Vicus Therapeutics to Present at the BMO Capital Markets Focus on Healthcare Conference
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... San Diego , CA (PRWEB) , ... July ... ... Biopharma, announced the successful completion of a field clinical study of its canine ... being developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against ... were $697 million compared to $701 million in the ... and changes in foreign currency exchange rates decreased sales ... , By business unit, organic sales growth was 6% ... Commercial. , Reported diluted EPS was $0.98 compared ...
(Date:7/29/2015)... 2015 Sanofi, un leader ... résultats pour le premier semestre 2015. Le Directeur ... Visionner l,interview vidéo et lire la ... Au sommaire de l,interview :  ... croissance - Diabète - ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Wisconsin's most prominent pharmaceutical companies has been purchased, its ... result in a continued limited presence in Wisconsin, but ... science industry, increase distribution of their drug and has ... Genzyme Corp. , a Massachusetts-based pharmaceutical firm, announced on ...
... When FedEx/Kinkos needed to dispose of 1,100 used ... a cost of $200,000 to the company and a ... Aidmatrix to essentially recycle the machines by donating them to ... , ,In case you ever wondered about what happened to ...
... 27 the U.S. Supreme Court decided Metro-Goldwyn-Mayer Studios ... affects how software companies and other technology providers will ... used to play, transmit or store copyrighted content. , ... of MGM, reversing a lower court decision favoring defendants ...
Cached Biology Technology:Genzyme acquistion of Bone Care approved, significant impact forecast 2Genzyme acquistion of Bone Care approved, significant impact forecast 3Genzyme acquistion of Bone Care approved, significant impact forecast 4Internet charity link has a Wisconsin flavor in CEO Scott McCallum 2Internet charity link has a Wisconsin flavor in CEO Scott McCallum 3Tech vendors could be liable for customer behavior - and not just file sharing 2Tech vendors could be liable for customer behavior - and not just file sharing 3
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... remarkable eyes of a marine crustacean could inspire the next ... study from the University of Bristol published today in ... are found on the Great Barrier Reef in Australia and ... They can see in twelve colours (humans see in only ...
... 23 GenVault Corporation, the leader in ambient temperature ... announced that David Wellis, Ph.D., GenVault,s President and CEO, ... place on October 26th and 27th in La Jolla, ... an overview of the company together with recent customer, ...
... A bioethicist who specializes in moral dilemmas families face ... the first-ever March of Dimes Distinguished Lectureship in Perinatal Bioethics. ... John D. Lantos, MD, a nationally-recognized pediatrician and ethicist, delivered ... at the American Society of Bioethics and Humanities, 11th annual ...
Cached Biology News:Mantis shrimps could show us the way to a better DVD 2GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2March of Dimes establishes 2 new perinatal bioethics awards 2
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
FITC~Bovine Serum Albumin...
Biology Products: